Left ventricular (LV) torsion may be an important component of normal LV systolic function. However, its mechanics remain unresolved. Two-dimensional (2-D) strain imaging is increasingly used to quantify LV torsion in the clinical setting. Telmisartan has cardioreparative effects, including attenuation of subendocardial myocardial fibrosis and improvement of LV remodelling. To clarify the mechanisms of LV torsion, in the present study, we evaluated changes in LV longitudinal deformation and torsion after medication with telmisartan using 2-D strain imaging in patients with hypertension (HT).
Introduction
Previous histologic study 1 demonstrated that architecture of the left ventricular (LV) myocardium consists of longitudinal fibres in the subendocardial layer, circumferential fibres in the mid-wall layer, and longitudinal fibres in the subepicardial layer. LV function is determined by both deformations of individual fibres and sheet arrangements formed from multiple myocytes. 2, 3 LV torsion can be created by dynamic interaction between right-handed helix in subendocardium and left-handed helix in subepicardium. 4 A newly developed two-dimensional (2-D) strain imaging has provided a relatively simple technique for the evaluation of torsion. 5, 6 There are many factors that affect LV torsion, whereas its mechanisms remain unresolved. 7 Telmisartan is a angiotensin II receptor blocker, and also is a partial peroxisome proliferator-activated receptor gamma (PPAR-g) agonist. This antihypertensive agent seems to have cardioreparative effects on LV geometry 8, 9 and subendocardial myocardial fibrosis 10, 11 in patients with hypertension (HT). In the present study, we sought to speculate the mechanisms on the LV torsion by taking advantage of treatment with telmisartan in patients with HT using 2-D strain imaging.
Methods

Study population
Between September 2006 and March 2008, 37 consecutive patients diagnosed with a history of HT for more than 2 years and never-treated HT was recruited from our outpatient clinic. Patients were defined as hypertensive if their systolic blood pressure (BP) was at least 140 mmHg (mean: 176 + 20 mmHg), diastolic BP at least 90 mmHg (mean: 98 + 12 mmHg), or both on two or more hospital visits at 1-week intervals before treatment with telmisartan. Exclusion criteria were atrial fibrillation, history of coronary artery disease, regional wall motion abnormalities, heart failure, diabetes mellitus, previous stroke, significant valvular disease, secondary causes of HT, congenital heart disease, cardiomyopathy, pericardial disease, cor pulmonale, or inadequate echocardiographic recordings.
The purpose of the study was explained and informed consent to participate was obtained from each patient. Telmisartan was administered to all patients at a daily dose of 20 -40 mg for 12 consecutive months. None of the patients received any medication other than telmisartan to treat their HT. During this period, the patients were asked to come to the hospital every 2 weeks to assess compliance and for BP and pulse/heart rate measurements.
Some studies 12, 13 reported that transmitral flow velocity, tissue Doppler, and strain imaging variables are influenced by the afterload. Therefore, all participants were studied by standard M-mode and 2-D, pulsed Doppler, tissue Doppler, and 2-D strain echocardiography at the two points after medication with telmisartan had been continued for 1 -2 months with values of systolic BP ,140 mmHg and diastolic BP ,90 mmHg (phase I) and for 12 months (phase II).
A total of 30 age-matched controls, selected from 65 individuals presenting with symptoms of chest pain, palpitations, dyspnoea, or heart murmurs in whom phonocardiography, conventional echocardiography, and exercise testing were normal, served as a control group. These patients also gave informed consent before study entry.
Conventional, pulsed Doppler, and tissue Doppler echocardiography
All echocardiographic measurements were performed using a commercially available ultrasound system (Vivid 7, General Electric Healthcare, Milwaukee, WI, USA) equipped with a harmonic 4.0 MHz variable -frequency phased-array transducer.
The end-diastolic LV diameter (Dd), end-systolic LV diameter (Ds), end-diastolic thickness of the ventricular septum (VSth), and enddiastolic thickness of the LV posterior wall (PWth) were measured by M-mode echocardiography. By using these parameters, we calculated the LV mass 14 and relative LV wall thickness as follows:
Relative LV wall thickness = 2 × PWth Dd
The LV mass index (g/m 2 ) was determined by dividing the LV mass measurement by the body surface area. The LV end-diastolic volume (EDV) and end-systolic volume (ESV) were calculated from the apical two-chamber and four-chamber views using a modified Simpson's method. The LV ejection fraction was calculated as follows:
Left atrial volume was measured offline using the biplane area -length method from the apical two-chamber and four-chamber views and was indexed to the body surface area. The transmitral flow velocity pattern was recorded from the apical four-chamber view. The following parameters were measured: peak early diastolic velocity (E), peak atrial systolic velocity (A), their ratio (E/A), and the deceleration time of E wave (E-DT). The Tei index was measured from the transmitral flow and LV outflow velocity time intervals and was calculated by the total isovolumic (contraction and relaxation) time divided by ejection time. 15 The mitral annular motion velocity was recorded at the LV posterior wall site in the apical LV long-axis view by pulsed tissue Doppler echocardiography. The peak systolic motion velocity (s ′ ), peak early diastolic motion velocity (e ′ ), peak motion velocity during atrial systole (a ′ ), and ratio of E to e ′ (E/e ′ ) were determined 16 (although e ′ was measured at the LV posterior wall site of the mitral annulus in this study).
Two-dimensional strain imaging
We acquired LV short-axis views at the apical, mid, and basal levels, and LV apical two-chamber and four-chamber views using a high frame rate (65 -69 frames/s). The basal short-axis view contained the mitral valve, the mid short-axis view contained the chordae tendineae, and the apical short-axis view was acquired distal to the papillary muscles. At each plane, three consecutive cardiac cycles were acquired at end-expiration breath holding and stored digitally on a hard disk for offline analysis. Image analysis was performed offline on a PC workstation using custom analysis software (Echopac PC, Version 6.0.X, GE Healthcare, Fairfield, CT, USA). The LV endocardial border of the endsystolic frame was manually traced. On the basis of this line, the computer automatically created a region of interest including the entire transmural wall in all patients, and the software selected natural acoustic markers moving with the tissue. Automatic frame-by-frame tracking of these markers during the cardiac cycle (2-D systolic time-interval method) yielded a measure of rotation, rotational velocity, strain, and strain rate at any point of myocardium. The LV was divided into 18 segments and each segment was individually analysed. With the use of a dedicated software package, 2-D LV strain, strain rate, and rotation were measured as previously described. 5, 6 In the present study, longitudinal strain and strain rate were assessed in the six LV walls on the apical two-chamber view and in the six LV walls on the apical four-chamber view, and their average values were used for comparisons among the control group and phases I and II of the HT group. Circumferential strain and strain rate were assessed in the six LV walls on the parasternal LV short-axis view at the level of the chordae tendineae, and their average values were used for comparison. Radial strain and strain rate were also assessed in the six LV walls on the parasternal LV short-axis view at the level of the chordae tendineae, and each value was used for the comparison.
LV rotation and torsion were assessed using parasternal LV shortaxis views at the basal level, including the mitral valves, and at the apical level excluding the papillary muscles. An effort was made to make both of the LV short-axis sections as circular as possible. When viewed from the LV apex, the systolic rotation of the base was clockwise and is expressed as a negative value, whereas the rotation of the apex was counterclockwise and is expressed as a positive value. Therefore, torsion is defined as the difference between the apical and basal rotation and was divided by end-diastolic LV longitudinal length between the LV apex and the mitral plane. 17 We recorded LV rotation and rotational velocity profiles during a cardiac cycle at the base and apex using the software package described above. Data points representing the basal and apical LV rotation and rotational velocity were exported to a spreadsheet program (Microsoft Excel, Microsoft Corp, Redmond, WA, USA) to create LV torsion and torsion rate profiles. All variables in the present study represent the mean value of measurements taken in three consecutive cardiac cycles.
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Statistical analysis
Values are expressed as the mean + SD. Comparisons of variables between the control group and phase I or II of the HT group were performed using the unpaired Student's t-test. Mean values for the clinical, M-mode, 2-D, pulsed Doppler, tissue Doppler, and 2-D strain echocardiographic variables of the phases I and II after administration of telmisartan were compared with a two-factor analysis of variance (ANOVA) for repeated measurements. The significance of correlations between the LV torsion and other parameters based on the difference in values of phases I and II were determined by linear regression analysis. A P-value , 0.05 was considered statistically significant.
Results
Control group vs. phase I or II of HT group
There were no significant differences in the systolic and diastolic BP and heart rate between the control group and phase I or II of the HT group ( Table 1) . The total cholesterol and low-density lipoprotein (LDL) cholesterol in the phase II were significantly lower, and triglycerides in the phase I was significantly greater compared with those of the control group. The end-diastolic ventricular septal thickness and LV mass index were significantly greater in the phase I than in the control group, whereas there were no significant differences between the control group and phase II ( Table 2 ). The peak A of the transmitral flow velocity and peak a ′ of the mitral annular motion velocity in the phases I and II were significant greater compared with those of the control group (Tables 2 and 3 ). There were no significant differences in the Tei index and E/e ′ among the three groups, but isovolumic relaxation time (IRT) was significantly shorter in the phase II than in the control group. The mean peak systolic strains and strain rates in the longitudinal and circumferential directions were significantly lower in the phase I than in the control group, whereas there were no significant differences between the control group and phase II ( Table 3 ). The mean peak early diastolic strain rates in all the three directions were significantly lower in the phase I than in the control group, whereas there were no significant differences between the control group and phase II. The mean peak atrial systolic strain rate in the longitudinal direction was significantly lower in the phase I than in the control group, whereas there was no significant difference between the control group and phase II. The torsion and torsional rate in the phase II tended to be lower compared with those of the control group, and those of the phase I tended to be greater compared with those of the control group. The untwisting rate was significantly lower in the phases I and II than in the control group.
Phase I vs. phase II of HT group
There were no significant differences in the systolic and diastolic BP and heart rate between the phases I and II ( Table 1) . The total cholesterol, triglycerides, LDL cholesterol, and uric acid were significantly decreased in the phase II than in the phase I. The end-diastolic ventricular septal and LV posterior wall thicknesses, relative LV wall thickness, LV mass index, E-DT, and IRT were significantly decreased in the phase II than in the phase I (Table 2, Figure 1 ). However, there were no significant changes in the LV ejection fraction, E/A, and Tei index between both phases. The s ′ , e ′ , and a ′ of the mitral annular motion velocity were significantly increased in the phase II than in the phase I, whereas there was no significant change in the E/e ′ between both phases ( Table 3) . The mean peak systolic strains in all the three directions and mean peak systolic strain rates in the longitudinal and circumferential directions were significantly increased in the phase II compared with the phase I. Also, the mean peak early diastolic strain rates in all the three directions and mean peak atrial systolic strain rate in the longitudinal direction were significantly increased in the phase II than in the phase I. The torsion, torsion/LV length, and torsional rate in the phase II were markedly decreased compared with those of the phase I (Figure 2) . LV posterior wall thicknesses and relative LV wall thickness, and was inversely correlated with end-diastolic LV diameter and LA volume index (Table 4) . However, there was no significant difference between the difference in LV torsion/LV length and LV mass index.
Correlations between the LV torsion and various echocardiographic parameters
Measurement variability
Images recorded at the phases I and II for velocity values, strain values, torsion, and untwisting values were interpreted by two experienced investigators in 15 randomly selected patients. To assess the variability of velocity and strain analysis, measurements were repeated from the 15 patients either by the same investigator or by two independent investigators. Intraobserver variability was 2.6 -4.0% for velocity values, 4.1 -5.2% for strain values, and 4.7 -6.8% for torsion and untwisting values. The interobserver variability was 3.9 -6.2% for velocity values, 5.5-7.0% for strain values, and 6.2 -7.8% for torsion and untwisting values. Also the test-retest variability for strain values, torsion, and untwisting values was 5.6 -8.2%. Significant correlations were noted between two measurements (r ¼ 0.86-0.92).
Discussion
The main findings on LV torsion of this study can be summarized as follows: administration with telmisartan for 12 months caused (i) decreased relative LV wall thickness and LV mass index; (ii) decreased peak LV torsion and torsional rate, which was correlated with changes in relative LV wall thickness rather than LV mass index; and (iii) increased peak systolic longitudinal strain and strain rate.
Recently, torsion has been gazed with deep interest as a potential novel index of LV function because the myofibre orientation changes continuously from right-handed helix in subendocardium to left-handed helix in subepicardium. 4 The LV apex rotates counterclockwise about the long axis of the heart, while the LV base rotates clockwise. As a result, the LV reveals torsional deformation, which is advantageous for LV ejection. The recent development of 2-D strain imaging has provided a relatively simple technique for the estimation of torsion. 5, 6 There are many factors that affect LV torsion, yet little is known about its determined mechanisms. Recent studies found that LV torsion is greater in patients with mild diastolic dysfunction (E/A , 1)
18,19 compared with normal subjects, and normalize in patients with moderate to severe diastolic dysfunction (E/A . 1). 19, 20 LV torsion depends on the relative contractility of the subendocardial and subepicardial myocardium. Therefore, these findings may be a result of impaired subendocardial fibre function due to subendocardial ischaemia and/or fibrosis 10, 11 in HT patients with comparatively mild LV diastolic dysfunction. It is well known that longitudinal LV contractility is first deteriorated in patients with LV diastolic dysfunction and preserved pump function, 18 and even in healthy elderly individuals. 21 However, the decrease in longitudinal shortening is compensated by an increase in the circumferential shortening and normal or increased LV torsion, Mechanisms of LV torsion evaluated by telmisartan and therefore both the parameters contribute to preserved LV ejection fraction. 20, 22 Also, previous study has shown increased LV torsion in patients with HT and concentric LV hypertrophy. 23 Accordingly, it is reasonable to infer that pivotal factors on the mechanisms of LV torsion are physiologic or pathologic fibrosis in the subendocardium, which is more vulnerable to fibrosis and pressure overload, and/or relative difference in torque between the subendocardial and subepicardial sides as a result of concentric LV hypertrophy. On the basis of this hypothesis, in the present study, we performed 2-D strain echocardiography in patients with HT, and examined the possible mechanisms of the LV torsion by utilizing the beneficial effects of telmisartan on LV structure and function.
In patients with HT, particularly with LV hypertrophy, connective tissue content is increased in the hypertrophied myocardium, 24 and pressure overload-related myocardial fibrosis is frequently identified in the subendocardial layer than in the subepicardial layer. 10 In addition, intramyocardial coronary flow reserve is exhausted, resulting in the myocardial ischaemia and fibrosis in the subendocardial layer. 25 Telmisartan is a unique agent that not only is an angiotensin II receptor blocker (ARB), but also is a partial PPAR-g agonist. ARBs suppress the LV remodelling possibly by reducing the matrix metalloproteinases (MMPs) related to myocardial fibrosis, and PPAR-g inactivates MMPs. 26 In an animal model, it was confirmed that telmisartan attenuates myocardial reactive fibrosis. 27 Furthermore, the HT, hypertension; LV, left ventricle; e ′ , peak early diastolic mitral annular motion velocity; a ′ , peak atrial systolic mitral annular motion velocity; s ′ , peak systolic mitral annular motion velocity; E/e ′ , ratio of peak early diastolic transmitral flow velocity to e ′ . *P , 0.05 vs. phase I. **P , 0.01 vs. phase I. ***P , 0.001 vs. phase I. ****P , 0.0001 vs. phase I.
§ P , 0.05 vs. control group. § § P , 0.01 vs. control group. § § § P , 0.001 vs. control group. § § § § P , 0.0001 vs. control group. effect of telmisartan on the myocardial collagen production, which contributes to LV hypertrophy, has been demonstrated in an animal model. 28 Therefore, not only BP reduction but also other drug-related mechanisms, including the selective activation of PPAR-g, may be involved in the regression of LV hypertrophy. 8, 9 In the present study, relative LV wall thickness and LV mass index were significantly reduced, peak systolic longitudinal strain and strain rate were markedly improved, and LV torsion and torsional rate were significantly decreased in the phase II than in the phase I. Furthermore, relative LV wall thickness, but not LV mass index, was an important factor for determining the LV torsion. These results support that LV torsion is increased by greater radius of the subepicardial side relative to the subendocardial side of the LV myocardium in patients with concentric LV hypertrophy. 29 A study using pulsed tissue Doppler echocardiography indicated the inverse correlation between the systolic myocardial velocity along the long axis and myocardial collagen content. 30 Another study 23 demonstrated that systolic longitudinal strain and LV torsion correlate with serum tissue inhibitor of MMP-1, which is a proteinase responsible for the degradation of collagen type I. Accordingly, from the results based on cardioreparative effects of telmisartan, we speculated that LV torsion is associated with (i) impairment of peak systolic longitudinal deformation probably due to subendocardial ischaemia or fibrosis compared with the preserved subepicardial fibre shortening, and/or (ii) greater radius of the subepicardial side relative to the subendocardial side along the long axis as a result of concentric LV hypertrophy. 
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However, a recent study has shown that total absence of the left pericardium induces a lack of LV torsion, whereas does not affect regional LV myocardial function evaluated by 2-D strain imaging. 31 On the basis of their results in the clinical setting, Weyman 7 reviewed that the presence of torsion does not seem essential for the ventricle to function normally, nor can it be used as a measure of systolic or diastolic function in all settings; therefore, further investigation will be needed to clarify the clinical importance of LV torsion.
Study limitations
There were several limitations of the present study. First, most software package of 2-D strain analysis average measurements over LV segments, including the full thickness of the myocardial wall. Therefore, it was impossible to differentiate between subendocardial and subepidcardial strains. Second, study population was of relatively small size, and the majority of the patients included had mild-to-moderate LV diastolic dysfunction and/or LV hypertrophy. Future studies consisting of a larger number of patients, including those with more stiffened LV or marked LV hypertrophy, are required to confirm the mechanisms of LV torsion. Third, we could not provide any markers of myocardial fibrosis, such as serum carboxy-terminal propeptide of procollagen type I, in the present study. Therefore, it is undetermined whether a reduced LV torsion in the phase II compared with the phase I is associated with the improvement in longitudinal subendocardial shortening related to the attenuation of subendocardial myocardial fibrosis or regression of LV hypertrophy. Finally, several patients received statin therapy during the course of the study. Therefore, our results may be modified by anti-inflammatory and anti-fibrotic effects of statins. 32 
Conclusion
Mechanisms of LV torsion were feasible by utilizing cardioreparative effects of telmisartan in patients with HT using 2-D strain imaging. We speculated that LV torsion is associated with (i) impaired subendocardial fibre function as a result of subendocardial ischaemia and/or fibrosis, and (ii) greater radius of the subepicardial side relative to the subendocardial side of the LV myocardium as a result of concentric LV hypertrophy. LV, left ventricle; LA, left atrium; BSA, body surface area; E, peak early diastolic velocity of transmitral flow; A, peak atrial systolic velocity of transmitral flow; E-DT, deceleration time from peak to baseline of the early diastolic transmitral flow velocity; NS, not significant.
